<DOC>
	<DOCNO>NCT00351403</DOCNO>
	<brief_summary>Patients chronic hepatitis C genotype 1 virus infection usually treat Interferon alfa plus Ribavirin 48 week . For patient might long , others short . An individually adapt therapy length 24 72 week determine dependence initial virus load time HCV RNA negativity . The primary objective compare cumulative rate sustain viral response ( SVR ) patient individually adapt therapy duration SVR rate historic patient collective 48 week standard therapy .</brief_summary>
	<brief_title>Individually Adapted Therapy Duration Treatment Chronic Hepatitis C Genotype 1 Infection</brief_title>
	<detailed_description>Further objective trial : To record tolerance therapy Peginterferon alfa-2b plus Ribavirin 72 week inclusive adverse reaction withdrawal rate . To evaluate biochemical response treatment ( ALT value therapy ) comparison virological response treatment . To evaluate validity withdrawal rule trial week 12 24 comparison 2-log-rule qualitative detection HCV RNA week 24 detection limit 50 IU/ml . To evaluate impact HCV RNA concentration therapy , HCV kinetic therapy response treatment different group . To evaluate impact serum concentration Ribavirin anaemia virological therapy response , well dependence serum concentration Ribavirin creatinine clearance comparison body weight .</detailed_description>
	<mesh_term>Infection</mesh_term>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis C , Chronic</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<mesh_term>Peginterferon alfa-2b</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<criteria>Patients chronic HCV infection ( HCV antibodies HCV RNA positive ) Presence HCV genotype 1 infection Presence compensate liver disease satisfy follow hematological biochemical minimum criterion : Hemoglobin value &gt; = 13 g/dl men , &gt; = 12 g/dl woman Leukocytes &gt; = 3.000/mm3 neutrophile granulocyte &gt; 1.500/mm3 Thrombocytes &gt; 80.000/mm3 Total bilirubin normal range Albumin normal range Serum creatinine normal range THS normal range Exclusion autoimmune hepatitis AlphaFetoprotein normal range Negative HIV test Negativity Hepatitis B surface antigen ( HbsAg ) Normal elevate ALT/GTP value screen At know diabetes mellitus hypertension ophthalmologic examination must perform Liver biopsy within last 12 month must confirm diagnosis chronic hepatitis A confirmation must give sexually active patient practice save method contraception therapy 6 ( woman ) 7 ( men ) month therapy Age &lt; 18 year , &gt; 70 year Previous treatment hepatitis c ( Peg ) Interferon alfa ( Peg ) Interferon alfa/Ribavirin Patients organ transplantation cornea hair Infection HCV genotype 2,3,4,5 6 Pregnant nursing woman Any reason liver disease chronic hepatitis C Suspected hypersensitivity Interferon , Peginterferon Ribavirin Participation clinical trial treatment investigational product 30 day inclusion study Patients kind hemoglobinopathy Documented liver disease advance state Liver cirrhosis Child B C Each know exist clinical condition might challenge participation completion clinical trial depression , psychosis , severe psychiatric disease , suicide ideation CNS trauma cramp need medicamentous treatment Relevant cardiovascular dysfunction last 6 month patient clinically relevant change ECG Insufficiently adjust diabetes mellitus Severe chronic lung disease ( e.g . COPD ) Immunologic diseases autoimmunediseases disease demand longtime treatment corticosteroid clinical trial Clinically relevant gout Abuse drug , alcohol pharmaceutical Patient clinically relevant change retina Missing ability willingness understand purpose study give write consent participate study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>February 2010</verification_date>
	<keyword>Chronic HCV infection</keyword>
	<keyword>Genotype 1</keyword>
	<keyword>Individually adapt therapy</keyword>
	<keyword>Peginterferon alfa-2b</keyword>
	<keyword>Ribavirin</keyword>
	<keyword>Sustained viral response ( SVR )</keyword>
</DOC>